Therapy News and Research

RSS
Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

UC San Diego, GSK collaborate to treat leukemia by eliminating cancer stem cells

UC San Diego, GSK collaborate to treat leukemia by eliminating cancer stem cells

International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

MGH investigators report that medication could augment benefits of bariatric surgery

MGH investigators report that medication could augment benefits of bariatric surgery

Computer model shows how cancerous tumors manipulate blood-vessel growth for their own benefit

Computer model shows how cancerous tumors manipulate blood-vessel growth for their own benefit

Faster weight gain during inpatient treatment safe, effective for anorexia patients

Faster weight gain during inpatient treatment safe, effective for anorexia patients

New research identifies potential treatment for primary effusion lymphoma

New research identifies potential treatment for primary effusion lymphoma

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

DME treatment evolves in favour of intravitreal anti-VEGF injections

DME treatment evolves in favour of intravitreal anti-VEGF injections

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

SISSA scientists create synthetic enzymes that can differentiate between active and inactive genes

SISSA scientists create synthetic enzymes that can differentiate between active and inactive genes

UVA earns national Women's Choice Awards for patient safety, patient satisfaction in orthopedics

UVA earns national Women's Choice Awards for patient safety, patient satisfaction in orthopedics

Cedars-Sinai researchers test new methods for preserving cognition in laboratory mice

Cedars-Sinai researchers test new methods for preserving cognition in laboratory mice

Study: Extended-field IMRT for cervical or endometrial cancer does not increase risk of duodenal toxicity

Study: Extended-field IMRT for cervical or endometrial cancer does not increase risk of duodenal toxicity

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.